Serum Institute News

Novavax Covid vaccine, to be made in India by SII, Shows 90.4% efficacy in US trial

Novavax Covid vaccine, to be made in India by SII, Shows 90.4% efficacy in US trial

Novavax on Monday announced that its Covid vaccine — NVX-CoV2373 —demonstrated 100% protection against moderate and severe disease with 90.4% efficacy overall in phase-3 trial. “NVX-CoV2373, recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19